



-FOR IMMEDIATE RELEASE-

Sopris Venture Capital Investment Propels DeLorean AI Forward in the AI Revolution

Cutting-Edge Firm Leverages Artificial Intelligence Systems to Improve Health of Millions at Scale

Miami, FL, August, 2023 – [DeLorean Artificial Intelligence, Inc.](#), the cutting-edge AI technology firm with its flagship product, Medical AI, becoming the first artificial intelligence to be biologically validated and applied to patient health at scale, has announced a significant investment from [Sopris Venture Capital](#), a leading name in the industry for over 20 years, reinforcing its position as a leader in employing AI to patient health at scale. Sopris has led DeLorean AI's Series A round of \$7.55M with fellow investors Pinta Capital Partners, led by Managing Director Joel Landau, and James Chow, former executive at Oak Street Health. This round brings total funding of DeLorean Artificial Intelligence, Inc. to ~\$11M.

This investment comes as DeLorean AI disrupts the healthcare industry by making AI accessible and easy-to-use for payers, providers, and governments. Combined with Sopris Venture Capital's discipline, multi-strategy approach, and supported by its strong foundation of long-term strategic capital, its structure will enable top level performance.

"We took our time looking for the right partner, and we found that in Sopris Venture Capital. Sopris' investment will propagate and accelerate the expansion and adoption of our Medical AI product not only in the USA but in Europe, the Middle East and Latin & South America. Sopris is allowing DeLorean AI to super charge our disruption of the healthcare industry, but more importantly, extending the lives of our clients." – [Severence M. MacLaughlin, Ph.D.](#), Founder and CEO of DeLorean AI.

Sopris Venture Capital is deeply committed to their portfolio companies, providing not only funding, but also guidance and partnership, shaping strategy and building management organizations, serving as strategic advisors, leveraging their strong network of industry relationships, and leveraging an experienced culture with a proven track record. Their offerings range from SaaS to Tech-Enabled Businesses in Healthcare.

"We recognize DeLorean AI's unmatched potential in reshaping the healthcare landscape via AI, and we're excited to support their revolutionary approach." – [Mark Groner](#), Partner at Sopris Venture Capital.

“DeLorean AI’s unique ability to generate hyperpersonalized real-time predictions, rather than mere forecasts, represents a new frontier in medical AI applications. We firmly believe that DeLorean AI is not just predicting the future of AI – they’re building it.” – [Andy Paul](#), Founder and CEO of Sopris Venture Capital.

Distinct from traditional AI applications that primarily concentrate on forecasting, DeLorean AI is carving a new path by centering its work on the ability to generate predictions that are delivered in real-time with next best actions – allowing medical personnel to drive better treatment modalities to prevent future health challenges. This ground-breaking approach is already delivering robust revenue growth for an impressive portfolio of Fortune 500 clients, differentiating it from competitors in the AI landscape.

Dr. MacLaughlin, the CEO and Founder of DeLorean AI, expressed his views on the current state of AI investment, "We have developed a product through years of R&D. Our product is tried, tested and biologically validated. Healthcare CEO’s now have a choice between a tested Medical AI product that improves health and extends lives or unproven services? Our approach offers a clear path to ROI, shifting the paradigm from mere forecasting to proactive prediction."

In addition to its Medical AI solution, DeLorean AI holds patent-pending rights to several proprietary AI capabilities, including CPG Sales AI, Service Ticket Analysis (Ticket Analysis Prediction Engine AI – TAPE AI, Customer Relations Management AI (CRM AI), among others. Both AI solutions for Sales and Healthcare have already proven their value by significantly increasing sales and improving health outcomes respectively, while decreasing associated costs.

CRM AI, DeLorean AI's first patented product, can predict the winnability of a deal in addition to the financial impacts of deals on revenue generation and costs. It works seamlessly with any CRM platform, and its ability to analyze structured or unstructured data to guide business decisions has led to a proven 15% increase in sales for clients.

In the healthcare sector, the firm's Medical AI offers a predictive and proactive approach to treatment by creating mathematical profiles of patient journeys and treatment methodologies. This has resulted in substantial cost savings and better health outcomes for patients, as well as notable reductions in medical costs as much as \$100 per member per month.

The investment in DeLorean AI comes at a time when the AI sector is experiencing explosive growth. The market is currently valued at approximately \$380 billion and is projected to grow annually by ~40% over the next 8 years. This could see the economic impact rise to about \$16 trillion by 2030.

With a firm belief in the ROI of AI investment, Dr. MacLaughlin says, "Companies currently investing in AI are seeing a 17% ROI, compared to companies running decentralized science projects which studies have shown to actually decrease margins by -5%. Our patented Systems of Intelligence are disrupting the global market."

###

About DeLorean.AI

DeLorean.AI is a pioneering AI technology firm that builds sentient and semi-sentient systems of intelligence to address business and economic challenges for large Fortune 500 companies. Their patent-pending machines, algorithms, and systems have been developed to predict real-time revenue-generating outcomes for clients. For more information, please visit www.delorean.ai.